

Corrigendum

Protective Effects of Silymarin on Gentamicin-Induced Nephrotoxicity in Infectious Patients: A Randomized Double Blinded Placebo-Controlled Clinical Trial

Motahareh Mahi-birjand^{1,2}, Iman Karimzadeh³, Asghar Zarban⁴, Meghdad Abdollahpour-Alitappeh⁵, Seyed Alireza Saadatjoo⁶, Masood Ziaee^{1*}

¹Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

²Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran.

³Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran.

⁴Department of Clinical Biochemistry, faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

⁵Cellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan, Iran.

⁶Department of Nursing, Birjand University of Medical Sciences, Birjand, Iran.

***Corresponding Author:** Email: dr.m.ziaee@gmail.com

In the published article, “Mahi-Birjand M, Karimzadeh I, Zarban A, Abdollahpour-Alitappeh M, Saadatjoo SA, Ziaee M. Protective effects of silymarin on gentamicin-induced nephrotoxicity in infectious patients: a randomized double blinded placebo-controlled clinical trial. *Pharmaceutical Sciences*. 2020;26(3):287-95. doi: 10.34172/PS.2020.33”. The ethics approval code should be corrected from IR.SUMS.REC.1397.330 to IR.SUMS.REC.1397.329 and The IRCT registration number should be corrected to IRCT20161010030246N3 and the study start date should be corrected from April 2017 to November 2018. These corrections are administrative in nature and do not affect the study design, methodology, results, interpretation, or conclusions of the article. The authors apologize for any inconvenience this may have caused.